press release

2.11.19

Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development

SAN DIEGO, Feb. 12, 2019 -- Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019.

“We are pleased to present important research of Epic and our partners that demonstrates how our clinical solutions help accelerate development of novel immuno-oncology drugs and other drug classes by optimizing patient selection and monitoring response to therapy,” said Katherine Atkinson, Chief Commercial Officer at Epic. “More than 65 biopharmaceutical partners are currently utilizing our non-invasive liquid biopsy assays leveraging digital pathology, machine learning and artificial intelligence to enrich their clinical trial populations and for biomarker validation. We look forward to sharing advancements on our functional cell profiling (FCP) technology platform and unique clinical insights it can generate with industry members and genitourinary oncologists at the symposium.”

Presentation Type: Poster (Abstract: 398)

Title: Circulating cellular biomarkers associated with delayed time to progression among bladder cancer patients treated with immune checkpoint inhibitors

Presenter: Vadim Koshkin, M.D., University of California San Francisco

Date and Time: Friday, Feb. 15, 12:15-1:45 p.m. PT and 5:15-6:15 p.m. PT

Summary: In a preliminary analysis among metastatic bladder cancer patients treated with immune checkpoint inhibitors, patients with an increased baseline circulating tumor cell (CTC) count had a statistically non-significant trend towards shorter time to progression, whereas increased baseline CD4 cells had an association with delayed time to progression.

Presentation Type: Poster (Abstract: TPS328)

Title: A Phase 2 trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects

Presenter: Simon Chowdhury, M.D., Ph.D., Guy’s and St. Thomas’ Hospital

Date and Time: Thursday, Feb. 14, 11:30 a.m.- 1:00 p.m. PT and 5:30-6:30 p.m. PT

Summary: BeiGene and research collaborators are evaluating investigational PARP inhibitor pamiparib in a Phase 2 clinical trial that utilizes the Epic HRD Test to identify HRD-positive patients with metastatic castration-resistant prostate cancer and to monitor therapeutic efficacy.

Presentation Type: Poster (Abstract: 379)

Title: Circulating tumor cell (CTC) enumeration in patients with metastatic genitourinary (mGU) tumors treated in a phase 1 study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi)

Presenter: Zishuo Hu, National Institutes of Health

Date and Time: Friday, Feb. 15, 12:15-1:45 p.m. PT and 5:15-6:15 p.m. PT

Summary: Utilizing circulating tumor cells as biomarkers for clinical outcomes, patients with metastatic genitourinary tumors treated with combination therapy cabozantinib and nivolumab +/- ipilimumab demonstrated lower CTCs were associated with better clinical outcomes.

Presentation Type: Poster (Abstract: 225)

Title: Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC

Presenter: Howard Scher, M.D., FASCO, Memorial Sloan Kettering Cancer Center

Date and Time: Thursday, Feb. 14, 11:30 a.m.-1:00 p.m. PT and 5:30-6:30 p.m. PT

Summary: Circulating tumor cells in blood samples from patients with metastatic castration-resistant prostate cancer were characterized by Epic’s platform, demonstrating CTC morphology can be used as early detection of resistance to standard of care drugs.

About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego. Further information is available on the Company's website, www.epicsciences.com. Stay in touch on LinkedIn or on Twitter @EpicSciences.

Epic Sciences Media Contact: Jennifer Guzman, Epic Sciences, jennifer.guzman@epicsciences.com, 858-216-2217